PP64 Prognostic relevance of isocitrate dehydrogenase I and II mutations and MGMT promoter hypermethylation in diffuse astrocytomas

Lorella Valletta; Sara Guzzetti; Anna Luisa Di Stefano; Emanuela Maderna; Bianca Pollo; Gaetano Finocchiaro; Marica Eoli

doi:10.1016/s1359-6349(09)72218-9

ScienceGate Book Chapters

JOURNAL ARTICLE

PP64 Prognostic relevance of isocitrate dehydrogenase I and II mutations and MGMT promoter hypermethylation in diffuse astrocytomas

Lorella Valletta Sara Guzzetti Anna Luisa Di Stefano Emanuela Maderna Bianca Pollo Gaetano Finocchiaro Marica Eoli

Year: 2009 Journal: European Journal of Cancer Supplements Vol: 7 (4)Pages: 32-32 Publisher: Elsevier BV

DOI: 10.1016/s1359-6349(09)72218-9

Get Full-Text PDF Get Analytical Report

Keywords:

IDH1 IDH2 Isocitrate dehydrogenase Immunohistochemistry Anaplastic astrocytoma Mutation Pathology Glioma Oligodendroglioma PTEN Biology Cancer research Astrocytoma Medicine Gene Genetics Apoptosis PI3K/AKT/mTOR pathway Enzyme

Metrics

Cited By

0.00

FWCI (Field Weighted Citation Impact)

Refs

0.06

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Topics

Glioma Diagnosis and Treatment

Health Sciences → Medicine → Genetics

PP64 Prognostic relevance of isocitrate dehydrogenase I and II mutations and MGMT promoter hypermethylation in diffuse astrocytomas

Metrics

Topics

Related Documents

Diffuse Astrocytomas: Immunohistochemistry of MGMT Expression

Isocitrate dehydrogenase 1 and 2 genes mutations and MGMT methylation in gliomas

PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations

Prognostic significance of MGMT promoter methylation in diffuse glioma patients

Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas